SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2018

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of receivables, net

	December 31,
	2018		2017
Trade receivables, net of allowances of $(25,342) and $(22,050), respectively	$	299,407	$	317,004
Rebate receivables		22,375		12,847
Other receivables		4,820		2,240
	$	326,602	$	332,091

Schedule of allowance for doubtful accounts

	Year Ended December 31,
	2018		2017		2016
Beginning balance	$	(22,050)	$	(15,257)	$	(8,123)
Charged to expense		(8,660)		(9,424)		(9,534)
Write-offs, net of recoveries		5,368		2,631		2,400
Ending balance	$	(25,342)	$	(22,050)	$	(15,257)

Schedule of disaggregation of net sales by therapeutic categories for the Specialty segment and by product and service distribution channels for the PBM segment

	Year Ended December 31,
	2018		2017		2016
Specialty Segment:
Oncology	$	2,788,154	$	2,545,708	$	2,102,130
Specialty infusion		704,872		617,904		505,240
Immunology		555,115		561,730		644,173
Hepatitis		148,470		281,063		583,751
Other		594,226		466,452		575,094
Total Specialty segment		4,790,837		4,472,857		4,410,388
PBM Segment:
Retail networks		549,760		5,166		—
Specialty pharmacy		88,457		2,914		—
Mail order		68,158		2,261		—
Other		23,080		2,032		—
Total PBM segment		729,455		12,373		—
Inter-segment eliminations		(27,768)		—		—
Total net sales	$	5,492,524	$	4,485,230	$	4,410,388